ReviewArchives of microbiology2025
Exploring fungal survival mechanisms: toward next-generation antifungal therapies against Candida spp.
Review in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida Spp are predominant opportunistic fungal pathogens responsible for a broad spectrum of infections, ranging from superficial mucosal candidiasis to life-threatening systemic diseases, particularly in immunocompromised individuals. Its complex biology and adaptive mechanisms contribute to pathogenicity and antifungal resistance, presenting significant therapeutic challenges. This review aimed to explore fungal survival mechanisms that can be exploited for the development of antifungal drugs. Key structural drug target components include the fungal cell wall, comprising β-glucan, chitin, and the plasma membrane, as well as ergosterol, which serve as critical targets for antifungal intervention. Biosynthesis inhibitors show promise in compromising cell integrity. Biofilm formation, driven by quorum sensing and extracellular matrix production, further enhances resistance to antifungal agents and host immune responses. Virulence factors, including hyphal wall protein 1, secreted aspartyl proteinases, and phospholipases, facilitate adhesion, invasion, and immune modulation, making them attractive targets for therapeutic development. Additionally, stress response pathways, such as the Hsp90 calcineurin axis and oxidative stress regulators, offer novel avenues for developing new antifungal treatments. Metabolic flexibility, involving amino acid biosynthesis and the glyoxylate cycle, underpins fungal adaptation to the host environment and presents further opportunities for targeted intervention. This review explores the multifaceted survival strategies of Candida Spp. and highlights molecular pathways that can be exploited for antifungal drug development. Advancing our understanding of these mechanisms is crucial for the development of next-generation therapeutics that aim to overcome resistance, enhance treatment efficacy, and improve patient outcomes. A multidisciplinary approach integrating molecular biology, pharmacology, and clinical sciences is vital for translating these insights into effective antifungal strategies.
Indexed as
Identifiers
41081904What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.